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Table 1. Viral infections
Viral infections ADV EBV CMV BKV HHV-6
Prevalance 66/124 (53%) 47/124 (38%) 25/124 (20%) 26/48 (54%) 23/77 (30%)
Viremia only (n) 16 35 16 1 7
Disseminated disease (n) 29 9 8 14 4
Reduced-intensity conditioning 39/60 (65%) 19/60 (32%) 13/60 (22%) 7/20 (35%) 14/40 (35%)
Myeloablative conditioning
With ATG 26/55 (47%) 26/55 (47%) 12/55 (22%) 19/26 (73%) 8/32 (25%)
Without ATG 1/9 (11%) 2/9 (22%) 0 (0%) 0/2 (0%) 1/5 (20%)
Fanconi anemia (T-cell depleted) 5/14 (36%) 4/14 (29%) 4/14 (29%) 6/9 (67%) 2/7 (29%)
Median post-HSCT day
of viral detection (range)
26 (0-341) 42 (4-763) 15 (0-78) 36 (13-119) 86 (1-419)
Viremia was defined as the presence of virus in blood. Disseminated infection was defined as virus detection in at least two different organ systems.
N: patients with a specified condition, (%) percentage of patients affected. Myeloablative conditioning regimen: Busulfan/Cyclophosphamide/Anti-
thymocyte Globulin (ATG) or Cyclophosphamide/TBI. Reduced-intensity conditioning regimen:Alemtuzumab/Fludarabine/Melphalan
S316 Poster Session Ireceived a reduced-intensity conditioning (RIC) regimen, 14 Fan-
coni anemia patients received RIC regimen with T-cell depletion
of the graft. All patients were monitored for cytomegalovirus
(CMV), Epstein-Barr virus (EBV), adenovirus (ADV) weekly in
blood by PCR testing until day +100. Human Herpes Virus-6
(HHV-6) and BK virus (BKV) were monitored when clinically indi-
cated. Viral infection is defined a quantitative PCR detection in
blood or qualitative detection in stool, urine, body fluids or relevant
tissue.
Results: Table 1 demonstrates the prevalence and features of most
common viral infections. Overall survival was 70% with viral infec-
tion as the cause of death in 12 patients (10%).
Discussion:Adenovirus and BK virus were themost prevalent infec-
tions, detected in half of the transplant patients with adenovirusmost
likely to be disseminated. The use of Alemtuzumab, ATG and T-cell
depletion is associated with increased risk of viral infection. We ob-
served a higher prevalence of Adenovirus infections compared to
other reports, likely due to high percentage of unrelated donors
and use of Alemtuzumab and ATG in these patients. Our data rein-
force the importance of ADV as a potential pathogen causing a high
rate of disseminated infection in transplant recipients.298
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Introduction: A number of studies have demonstrated that G-CSF
can fasten neutrophil recovery in patients undergoing high-dose che-
motherapy (HDT) and transplantation of autologous peripheral
blood progenitor cells (PBPCT). However, the only measure to cor-
rect post-transplant thrombocytopenia is still donor platelets trans-
fusions. Recently, immune thrombocytopenic purpura management
has changed with introduction of thrombopoietin receptor agonists
(TRA), which were highly effective and safe in such patients. To
date, the only two TRA are available – romiplostim and eltrombo-
pag. It is possible that administration of TRA can significantly alter
clinical course of patients undergoing HDT. To address this ques-
tion, we initiated a pilot study to assess the efficacy of TRA after
HDT with PBPCT.
Patients and Methods: Seven patients (median age, 45 years; range
21-56; 6male and 1 female) suffered from non-Hodgkin’s lymphoma
(n5 2), Hodgkin’s lymphoma (n5 2) and multiple myeloma (n5 3)
were treated with HDT and PBPCTwith romiplostim support. Ro-
miplostimwas given subcutaneously at a dose of 250 mg on day of au-
tologous PBPC reinfusion. Twelve patients (median age, 39 years;
range 19-64; 6 male and 6 female) with NHL (n 5 6), HD (n 5 5)
and MM (n 5 1) were enrolled in the control group (without romi-
plostim). The end points of this study were the times of plateletsrecovery (TPR), the duration of thrombocytopenia, and the duration
of hospitalization.
Statistical analysis: Variable comparisons were evaluated by non-
parametric statistical methods (Mann-Whithey U test for continu-
ous variables and Fisher exact and Chi-square tests for categorical
variables).
Results:The duration of thrombocytopenia grade III was 10.7 days
in the romiplostim and 19.0 days in the control group (p 5 0.044).
The duration of thrombocytopenia grade IV was 6.9 and 13.8 days
in average groups, resp. (p 5 0.259). TPR grade III was 13.9 days
for romiplostim group and 22.2 days for control group (p 5
0.044). TPR grade IV was 13.0 and 18.7 days according to study
groups (p 5 0.035). The duration of hospitalization was 27.9 in
the romiplostim and 36.7 days in the control group (p 5 0.021).
Conclusion: This study demonstrates a tendency that the duration
of thrombocytopenia and hospital stay, the times of platelet recovery
are shortened when romiplostim is administered after HDT and
PBPCT. It seems highly likely that the use of romiplostim in setting
of autologous transplants improves clinical course of patients under-
going HDT.299
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Background: Double stranded DNA viruses (dsDNA) viral infec-
tions continue to be a significant cause of morbidity andmortality af-
ter allogeneic hematopoietic stem cell transplantation (HSCT).
These include cytomegalovirus (CMV), Epstein-Barr virus (EBV),
Adenovirus (ADV), Human Herpes Virus-6 (HHV-6) and BK virus
(BK). Currently available antiviral therapy has variable efficacy and,
more importantly, is associated with significant hematologic and re-
nal toxicities. CMX001, an orally bioavailable lipid conjugate of ci-
dofovir, is under investigation for the prevention and treatment of
these dsDNA viruses. Clinical data concerning the use of CMX001
for treatment of ADV andCMVhave been reported. However, there
is limited information available on the use of CMX001 prior to en-
graftment in allogeneic HSCT recipients.
Methods:We report on 4 patients with dsDNA viruses treated with
CMX001 prior to engraftment after allogeneic HSCT. The median
age was 2.1 years (Range 0.5 to 9.8). The preparative regimen con-
sisted of Alemtuzumab, Fludarabine andMelaphalan for all patients.
All patients had received first-line antiviral therapy (Ganciclovir, Fo-
scarnet or Cidofvoir) before starting on CMX001. Virologic re-
sponse (VR) was defined as 99% drop from baseline or
